PhD defence: Natasha Amran Laursen
How should osteoporosis treatment be stopped?
Info about event
Time
Location
Room J116-111, Entrance J, Aarhus University Hospital
On Thursday 3 December 2026 at 14:00, Natasha Amran Laursen defends her PhD dissertation entitled “Mangement of Denosumab Discontinuation in Patients with Osteoporosis: Results from the ZOLARMAB2 Study, Nationwide Registry Data, Real-world Experience, and a Systematic Review”.
When treatment with the osteoporosis medication denosumab (Prolia) is stopped, bone mass can be lost rapidly. A new PhD project from Aarhus University, Health, investigates how best to manage this. The project was carried out by medical doctor Natasha Amran Laursen, who will defend her dissertation on 3 December 2026.
Denosumab strengthens bones and reduces the risk of fractures, but its effects wear off quickly after discontinuation. Subsequent treatment is therefore important to preserve the benefits achieved.
The project examines different patterns of denosumab treatment, with particular emphasis on subsequent treatment with zoledronate, a medication that slows bone breakdown. It combines clinical studies, Danish registry data, experience from routine clinical practice and a review of existing research. Changes in muscle mass, muscle strength and physical function after denosumab discontinuation are also investigated.
The aim is to contribute to better treatment strategies for patients with osteoporosis.
The summary is written by the PhD student.
The defence is public and takes place Room J116-111, Entrance J, Aarhus University Hospital. Please see the press release for more information.
Contact
PhD student Natasha Amran Laursen
Mail: natalu@clin.au.dk
Phone: +45 27893239